Correlation Between Rani Therapeutics and Equillium

Can any of the company-specific risk be diversified away by investing in both Rani Therapeutics and Equillium at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Rani Therapeutics and Equillium into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Rani Therapeutics Holdings and Equillium, you can compare the effects of market volatilities on Rani Therapeutics and Equillium and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Rani Therapeutics with a short position of Equillium. Check out your portfolio center. Please also check ongoing floating volatility patterns of Rani Therapeutics and Equillium.

Diversification Opportunities for Rani Therapeutics and Equillium

0.79

Correlation Coefficient

Rani Therapeutics  Equillium

Poor diversification

The 3 months correlation between Rani and Equillium is 0.79. Overlapping area represents the amount of risk that can be diversified away by holding Rani Therapeutics Holdings and Equillium in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Equillium and Rani Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Rani Therapeutics Holdings are associated (or correlated) with Equillium. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Equillium has no effect on the direction of Rani Therapeutics i.e., Rani Therapeutics and Equillium go up and down completely randomly.

Pair Corralation between Rani Therapeutics and Equillium

Given the investment horizon of 90 days Rani Therapeutics Holdings is expected to generate 0.68 times more return on investment than Equillium. However, Rani Therapeutics Holdings is 1.46 times less risky than Equillium. It trades about 0.01 of its potential returns per unit of risk. Equillium is currently generating about -0.03 per unit of risk. If you would invest  142.00  in Rani Therapeutics Holdings on December 27, 2024 and sell it today you would lose (8.00) from holding Rani Therapeutics Holdings or give up 5.63% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Rani Therapeutics Holdings  vs.  Equillium

Rani Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Rani Therapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Rani Therapeutics is not utilizing all of its potentials. The latest stock price confusion, may contribute to short-horizon losses for the traders.

Equillium

Risk-Adjusted Performance

Insignificant

Over the last 90 days Equillium has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in April 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Rani Therapeutics and Equillium

The main advantage of trading using opposite Rani Therapeutics and Equillium positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Rani Therapeutics position performs unexpectedly, Equillium can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will offset losses from the drop in Equillium's long position.

The idea behind Rani Therapeutics Holdings and Equillium pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.